Long-Acting Injectable Naltrexone Treatment of Alcohol Dependence in Primary Care vs. in Specialized Chemical Dependence Treatment: A Pilot Trial
The goal of the proposed project is to improve the primary care treatment of veterans with alcohol dependence. Alcohol dependence is a common behavioral health problem among veterans treated in VA primary care clinics. However, assessment and treatment of alcohol dependence in primary care remains problematic. Assessment of veterans with positive alcohol use screens may not always be completed and referrals to specialty care may not always be made. Moreover, the use of medications for alcohol dependence among veterans is rare, despite VA treatment guidelines that recommend such use. Finally, when medications are prescribed, patients may have difficulties with adherence.
The primary aim of this study is to assess the feasibility of long-acting injectable naltrexone provided through primary care (LAN/PC) versus long-acting injectable naltrexone in the specialized chemical dependence clinic (LAN/CDC). The secondary aim is to obtain preliminary assessments of the relative effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.
研究概览
研究类型
注册 (预期的)
阶段
- 第四阶段
联系人和位置
学习地点
-
-
New York
-
Syracuse、New York、美国、13210
- Syracuse VAMC
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
描述
Inclusion Criteria:
- Participants must be males or non-pregnant females between the ages of 18 and 69 who are receiving their primary medical care at the Syracuse VAMC.
- Participants must meet DSM-IV diagnostic criteria for current alcohol dependence.
- Participants must report drinking within the thirty days prior to study entry.
- Participants must receive approval from their primary care provider for study participation.
- Participants must be willing to consider accepting at least one of the two treatment conditions.
Exclusion Criteria:
- Participants with a current DSM-IV diagnosis of current opioid abuse or dependence, or in opioid withdrawal
- AST level is greater than 3 times the upper limit of the normal range
- Participants with a medical condition requiring opioid medication or a severe allergy to naltrexone
- Participants who received outpatient treatment at the Syracuse VA Chemical Dependence Clinic in the past 90 days
- Any unstable medical or psychiatric conditions in the judgment of the principal investigator or the participants primary care provider
学习计划
研究是如何设计的?
设计细节
- 主要用途:治疗
- 分配:随机化
- 介入模型:并行分配
- 屏蔽:无(打开标签)
研究衡量的是什么?
主要结果指标
结果测量 |
---|
Primary Outcomes: Feasibility of an injectable naltrexone study in the primary care setting.
|
次要结果测量
结果测量 |
---|
Secondary Outcome: Effectiveness of long-acting injectable naltrexone in primary care versus in the chemical dependence clinic.
|
合作者和调查者
调查人员
- 首席研究员:Steven L Batki, M.D.、Executive Director VA Center for Integrated Healthcare, Syracuse VA Medical Center
研究记录日期
研究主要日期
学习开始
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (估计)
研究记录更新
最后更新发布 (估计)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.
Injectable Naltrexone的临床试验
-
University of NebraskaInCor Heart Institute; VU University of Amsterdam完全的